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Objectives. We tested for an association between the
angiotensin-converting enzyme (ACE) DD polymorphic genotype
and myocardial infarction (MI) in a sample group composed
exclusively of women.
Background. The human ACE gene occurs with either an
insertion (I allele) or a deletion (D allele) of a 287-base pair (bp)
Alu element. Part of the variance in serum ACE levels may be
accounted for by this polymorphism. Also, the DD genotype has
been associated with an increased risk of MI in predominantly
male populations. However, the risk in women is poorly defined.
Methods. Genomic DNA was extracted from buffy coat blood
using a phenol/chloroform method. Angiotensin-converting en-
zyme alleles were identified using primers to bracket the insertion
region in intron 16. Amplification using polymerase chain reac-
tion allowed identification of a 490-bp (I allele) or a 190-bp (D
allele) product, or both.
Results. Allelic and genotypic frequencies in control subjects
were similar to those reported in mostly male populations, and
frequencies of genotypes were in the Hardy-Weinberg equilibrium.
In contrast, the distribution of genotypes in patients with MI
diverged from the equilibrium. Specifically, DD genotypic fre-
quency was increased in women with (n 5 141) versus without
(n 5 338) a previous MI (39% vs. 29%, odds ratio [OR] 1.54, 95%
confidence interval 1.02 to 2.32, p < 0.04). Risk was particularly
increased in women <60 years old (OR 2.04, p < 0.05). In
contrast, the DD genotype did not predict angiographic coronary
artery disease.
Conclusions. Consistent with findings in male-dominated pop-
ulations, a modest association of the ACE DD genotype with MI
was found in women. The basis for this association requires
further study.
(J Am Coll Cardiol 1998;31:790–6)
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The carboxypeptidase angiotensin-converting enzyme (ACE)
is widely distributed in endothelial tissue, where it catalyzes the
conversion of angiotensin I to angiotensin II, a potent vaso-
constrictor and vascular smooth muscle growth stimulant, and
the breakdown of the vasodilator bradykinin to kinin degrada-
tion products (1–4). By playing a pivotal role in these two
cardiovascular hormonal regulatory systems, ACE has an
important impact on cardiovascular structure and function
(1,5).
The ACE gene, located on chromosome 17, has been
cloned and found to be characterized in humans by a major
insertion/deletion polymorphism consisting of the presence
(insertion [I]) or absence (deletion [D]) of a 287–base pair
(bp) alu repeat sequence within intron 16 (6,7). About half of
the interindividual variance in serum ACE levels may be
accounted for by this polymorphism (8). A functional conse-
quence of the DD as compared with the II genotype is a
twofold increase in plasma ACE activity; intermediate levels
occur in heterozygotes (ID) (8).
The report of Cambien et al. (9) in 1992 generated substan-
tial interest in the possibility of a clinically important role of
the polymorphism (9): they reported that the frequency of the
DD genotype was increased in patients with myocardial infarc-
tion (MI), especially those at low risk, in a retrospective,
multicenter, case-control study. Many other reports have sub-
sequently appeared, with some supporting (10–15) and others
failing to find the association (16–20). A recent meta-analysis
of 15 studies in almost 9,000 patients and control subjects
confirmed an association with MI, albeit modest, with a mean
odds ratio (OR) of 1.26 (95% confidence interval [CI] 1.15 to
1.39, p , 0.001) for MI with the DD versus non-DD (ID/II)
genotype across all studies (21).
The great majority of patients with MI forming the study
series in the published reports have been men. In most reports,
only men were entered, the results were not analyzed by
gender or the associations were significant only for the larger
group of men (13,21). Thus, it remains unclear whether the
association of the I/D polymorphism with risk of MI applies to
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women. Moreover, the incidence, timing and known risk
factors for MI show differences in women as compared with
men (22,23). Rates of MI lag by a decade in women as
compared with men and show gender-related distinctions by
hormonal and diabetic status and lipid profile. Genetic risk
factors also might differ qualitatively and quantitatively by
gender. Thus, we sought to evaluate the association of the
ACE polymorphism with MI risk in a sample group composed
exclusively of women.
Methods
Study hypotheses. We prospectively postulated that, as
with men, women with the homozygous ACE deletion geno-
type (DD) would be at greater risk of MI than those without
this genotype (recessive model) (21). Also, we tested whether
MI was significantly associated with the presence of the D
allele (13).
Study group. The study group consisted of two subgroups.
The first, or pilot, subgroup (n 5 295) consisted of a subset of
a previous study of a mixed-gender group (13) prospectively
studied for an overall association of the I/D polymorphism with
MI. In this group there was a trend toward an association
between the D allele and MI in women, but it did not reach
significance (OR 1.40, p 5 0.26). We postulated that this was
due to the small number of women with MI in the study group
(n 5 36). Power calculations indicated that to evaluate a
relative risk $1.5 for the DD genotype in diseased versus
nondiseased patients with a power of 80% at an alpha level
#0.05 in a group of women with a control frequency of the DD
genotype of 28% (13,21), a sample of 179 subjects per group
would be required (GB-STAT for Windows).
Accordingly, we expanded the sample to 490 subjects, 53%
of whom had coronary artery disease (CAD) and 29% of whom
had a history of MI. The expanded sample was enriched for
those with a history of MI (n 5 105) to provide adequate
power to detect an OR for MI of ;1.5 for DD versus non-DD
(ID 1 II) genotypes.
Patient characteristics. All patients were women of unre-
stricted age who presented for angiography at LDS Hospital
because of either symptoms relating to suspected CAD or
unrelated conditions requiring angiographic evaluation (e.g.,
valvular disease, cardiomyopathy). The patients gave written,
informed consent for a blood draw for use in confidential
deoxyribonucleic acid (DNA) bank studies (13,24). The pa-
tients were drawn from a population primarily of Northern
European (Anglo-Scandinavian) descent (Utah, southwestern
Idaho and southeastern Wyoming) that is ethnically and
genetically representative of U.S. whites (25).
Key demographic characteristics for the patients were
captured on computerized angiographic data forms, including
age, gender and history of MI (24). Angiographic assessment
of CAD was determined by a review of angiograms by the
patient’s cardiologist and entered into the computer data base
in a format modified after the Coronary Artery Surgery Study
(CASS) protocol (24,26). Patients were designated as having
CAD if they had .60% stenosis in at least one coronary artery
or its major branch and no CAD if ,10% stenosis was present.
Other patients with minor CAD (10% to 60% stenosis) were
given an “indeterminate” CAD status and were not used in
genotype by CAD analyses. Final designations of MI and CAD
status were made after considering arteriographic and ven-
triculographic results, together with patient history, without
knowledge of DNA genotype. The control group included
angiographically studied patients without acute or old MI
regardless of CHD status.
DNA genotyping. Peripheral blood was collected in EDTA,
and the DNA was extracted from the leukocyte buffy coat by
phenol/chloroform extraction and alcohol precipitation as pre-
viously described (27). The ACE alleles were identified by the
amplified fragment length polymorphism method. This
method has been described elsewhere (7). Briefly, primers that
bracket the insertion region in intron 16 were used in the
polymerase chain reaction to produce either an amplified
490-bp (I allele) or a 190-bp (D allele) product, or both. The
upstream primer (59 to 39) was: CTGGAGACCACTC-
CCATCCTTTCT. The downstream primer (59 to 39) was:
GATGTGGCCATCACATTCGTCAGAT. Amplification was
for 30 cycles; each cycle consisted of a denaturation segment at
94°C for 1 min, an annealing segment at 62°C for 45 s and an
extension segment at 72°C for 1 min. A final extension segment
at 72°C for 5 min was included after the final cycle. All
suspected deletion mutants were reamplified using the down-
stream primer and a third primer (59 to 39: TTTGAGACG-
GAGTCTCGCTC); this combination produces a 408-bp prod-
uct for the insertion allele and no product for the deletion
allele (28). The products were visualized by electrophoresis
through 1.5% agarose gel, followed by staining with 1 mg/ml of
ethidium bromide in tris-borate-EDTA buffer. The genotype
was identified by an experienced observer who had no knowl-
edge of the patients’ clinical characteristics (Fig. 1).
Statistics. Comparisons between genotype frequencies
were done using chi-square analysis; ORs with 95% CIs were
calculated as previously described (29). No significant differ-
ence in the frequency of the DD genotype among patients with
MI was observed between the pilot and expanded patient
groups (p 5 0.46), so they were combined and considered
together as a single series in the presentation of the results.
A two-tailed p value #0.05 was considered significant for
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
bp 5 base pair
CAD 5 coronary artery disease
CI 5 confidence interval
D 5 deletion allele
DNA 5 deoxyribonucleic acid
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the primary hypothesis (risk of MI in women with the DD vs.
non-DD genotype). P values for secondary hypothesis testing
were not corrected for multiplicity of comparisons and should
be viewed with caution.
Results
Patient groups. A total of 490 women with angiographi-
cally defined CAD were studied; MI status was known for 479
of them (141 had a history MI and 338 did not). CAD was
severe in 250 patients, absent/minimal in 225 and intermediate
(10% to 60% stenosis) in 15, who were excluded (see Meth-
ods). Thus, 475 patients with either advanced or negligible
CAD and 479 with or without a known history of MI formed
the basis for the analysis. Patient characteristics are summa-
rized in Table 1. As expected, patients with CAD were older,
were more frequently hypertensive, diabetic and hyperlipid-
emic and more often tended to be smokers than those without
CAD. Common risk factors, including age, smoking and dia-
betes (trend), were more prevalent in patients with MI than in
control subjects.
Genotypic frequencies. Genotypic and D allelic frequen-
cies for the study groups are shown in Table 2. The control
group’s genotypic frequencies are in agreement with the
frequencies predicted by the Hardy-Weinberg equilibrium.
The D allelic frequency in the control groups without CAD
and without MI was 52% to 53%. These allelic and genotypic
frequencies also are similar to those previously reported in a
large European control population (9,30), as well as in a
smaller sample of control subjects from the western United
States (31) and in our previously reported, angiographically
assessed group from Utah (13). In contrast to control subjects,
the genotypic distribution in women with MI (but not CAD)
differed from Hardy-Weinberg expectations (chi-square statis-
tic 4.6, p 5 0.03).
Association between ACE I/D polymorphism and MI. A
significant increase in the frequency of the DD genotype versus
non-DD genotypes was found among women who had a
previous MI (n 5 141) compared with control subjects without
MI (with or without CAD; n 5 338)—39.0% versus 29.3%, OR
1.54, 95% CI 1.02 to 2.32, p 5 0.038 (Table 3, Fig. 2). Overall
(binomial) distributions of genotypes tended to differ between
MI and non-MI groups (Table 2), although these differences
did not achieve significance (p 5 0.11).
We also tested relative frequencies of the D allele in
Figure 1. Example of genotyping using polyacrylamide gel electro-
phoresis of polymerase chain reaction amplification products.
Table 1. Characteristics of Patients With Disease and Control Subjects*
Patients With MI
(n 5 141)
Control Group (no MI)
(n 5 338)
Patients
With CAD
(n 5 250)
Control Group
(no CAD)
(n 5 225)
Age (yr) 64 6 10‡ 60 6 11 64 6 10‡ 58 6 11
Range 48–89 17–84 28–89 17–81
Systolic blood pressure (mm Hg) 138 6 22 133 6 23 138 6 25† 129 6 19
Diastolic blood pressure (mm Hg) 76 6 12 74 6 11 74 6 12 76 6 11
Smoker 35‡ 20 26 21
Diabetes 22 16 25‡ 10
Hypercholesterolemia (%$ 220
mg/dl)
40 44 46† 28
*Based on 95% complete data for patients with myocardial infarction and 98% for patients with coronary artery
disease, except for cholesterol (data from subset of 127). †p # 0.05, ‡p # 0.001 versus control subjects. Data presented
are mean value 6 SD or percent of patients. CAD 5 coronary artery disease; MI 5 myocardial infarction.
Table 2. Genotypic and Allelic Frequencies in Patients With
Disease and Control Subjects
Group
ACE Genotype
D AlleleII ID DD
MI (n 5 141) 21.3 (30) 39.7 (56) 39.0 (55) 58.9 (166)
No MI (n 5 338) 23.1 (78) 47.6 (161) 29.3 (99) 53.1 (359)
CAD (n 5 250) 23.2 (58) 43.6 (109) 33.2 (83) 55.0 (275)
No CAD (n 5 225) 24.0 (54) 48.0 (108) 28.0 (63) 52.0 (234)
Data presented are percent (number) of patients. ACE 5 angiotensin-
converting enzyme; D 5 deletion allele; I 5 insertion allele; other abbreviations
as in Table 1.
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patients and control subjects (Table 2). D allelic frequency
tended to be enriched in patients with MI (59%) compared
with those without MI (53%), although the difference did not
achieve significance (p 5 0.11).
In contrast to DD, ID did not confer increased risk for MI
(OR 0.85 for ID vs. II, p 5 0.53). Frequencies of the II
genotype were similar in patients and control subjects (21% vs.
23%), whereas the D allele tended to occur in combination
with the I allele somewhat more frequently in control subjects
than in patients (48% vs. 40%, p 5 0.11).
We also tested a dominant model that compared risk of
disease (MI) of the DD 1 ID versus II genotypes; a significant
difference was not found (OR 1.11, p 5 0.67). Finally, a
homozygous comparison (DD vs. II) was made; a trend toward
an increased risk of DD was found (OR 1.44), although it did
not achieve significance (p 5 0.18), perhaps because of re-
duced power after excluding subjects with the ID polymorphism.
ACE polymorphism associations with MI by age. The
increased risk of MI associated with the DD polymorphism was
especially evident in younger women (,60 years old, n 5 187),
who showed an OR of 2.04 for MI (95% CI 1.00 to 4.16, p 5
0.048) when DD and non-DD genotypes were compared
(Table 3, Fig. 2). For older women ($60 years old, n 5 292),
the OR was 1.32 (CI 0.79 to 2.2, p 5 0.28) (Fig. 2). Overall
(binomial) distributions of the three I/D genotypes also dif-
fered significantly from those of age-comparable control
groups in younger women (p 5 0.037) but not in older women
(p 5 0.45) (Fig. 3). In contrast to age, smoking status, diabetes
and hypertension status did not tend to importantly influence
the relative risk of the ACE DD genotype for MI.
Association between ACE I/D polymorphism and CAD.
Consistent with the findings in our male-dominated series (13),
only small differences in DD genotypic and in D allelic
frequencies that were not significant were found in women
with angiographically documented CAD compared with those
without CAD (Table 2).
Discussion
Summary of study results. In this study of moderate size
(n 5 490) in women with angiographic assessment of CAD, we
found a statistically significant relation of moderate degree
between the DD genotype and risk of MI (OR 1.54). These
results are similar to those in our angiographically assessed
series of men (13) and in another meta-analysis (21). In an
exploratory subgroup analysis, an increased relative risk of MI
with the DD genotype was especially apparent in younger
women.
Comparison with previous studies. In our previous study
of 402 men (age range 30 to 64 years), the occurrence of MI
was significantly associated with the DD genotype, which was
present in 36% of patients with CAD plus MI and 25% of
control subjects with CAD and without MI (OR 1.63, p 5
0.02). The relative risk for MI of the DD genotype is thus
quantitatively similar in women and in men in our group and
may be even greater in younger women (Fig. 2).
A recent meta-analysis (15 studies) of the association
between the ACE I/D polymorphism and MI in male-
dominated populations found a mean OR of 1.26 for MI of the
DD versus ID 1 II genotypes (95% CI 1.15 to 1.39, p , 0.001)
(21). The distributions of genotypes in the control subjects
Figure 2. Odds ratios (diamonds) with 95% CIs (horizontal lines) for
DD versus non-DD genotypes among women (total group and accord-
ing to age ,60 and $60 years) and men (13) who were angiographi-
cally assessed.
Figure 3. Genotypic frequencies by age for patients with MI and
control subjects without MI. Distributions are significantly different for
patients with versus without MI who were ,60 (p , 0.04) but not $60
years old (p 5 0.45).
Table 3. DD and Non-DD Genotype Frequencies in Women by
Age and Myocardial Infarction Status
DD Non-DD*
All women
MI (n 5 141) 39.0%† 61.0%
No MI (n 5 338) 29.3% 70.7%
Women , 60 yr old
MI (n 5 42) 42.9%† 57.1%
No MI (n 5 145) 26.9% 73.1%
Women $ 60 yr old
MI (n 5 99) 37.4% 62.6%
No MI (n 5 193) 31.1% 68.9%
*Non-DD 5 ID 1 II. †p , 0.05 versus control group (no MI). Data are
presented as percentage of patients. Abbreviations as in Tables 1 and 2.
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were 22.7% for II, 49.0% for ID and 28.3% for DD, virtually
identical to those of our female control subjects (Table 2).
In contrast to most previous studies, Schuster et al. (32)
reported results separately by gender. Also, uniquely, they
found an association between the ACE I/D polymorphism and
MI for women but not for men. For the entire group (n 5 390),
a significant association between the homozygous (DD) geno-
type and MI was observed (relative risk 1.59, 95% CI 1.03 to
2.48). When the group was subclassified by gender, the results
were significant for women only (n 5 90, 25 with MI): 48% of
women with MI versus 23% of control subjects had the DD
genotype. However, the possibility that this apparent dichoto-
mous behavior according to gender was due to chance in their
relatively small study (especially with respect to women) was
not excluded. Indeed, the study has too few female patients
with MI to provide a reliable risk estimate of the I/D polymor-
phism by gender.
We did not find the intermediate-risk association between
MI and the ID genotype in women that has been reported in
some (but not all) male-dominated series (21). Schuster et al.
(32) also failed to observe an intermediate risk with the ID
genotype. Indeed, the ID genotype was more frequent among
women without MI (58%) than with MI (40%), whereas II
genotypic frequencies were similar in patients and control
subjects.
Given the known differences in some risk factors for MI by
gender (22,23), a real difference in the direction or magnitude
of the risk association in women with the ID genotype is
possible. However, we do not know of a compelling reason to
expect such a difference. Thus, the association (if any) between
the heterozygous (ID) genotype and MI risk in women should
be reexamined in other groups.
As in our study of men (13), we found little evidence for a
link between the I/D polymorphism and the pathophysiologic
steps leading to the development of atherosclerosis, as mani-
fested by angiographically defined coronary artery stenoses.
Rather, the link was observed with the transition from CAD to
MI (virtually all patients with MI also had CAD), suggesting
that the mechanisms associated with this transition should be
explored.
Pathophysiologic considerations. By its pivotal position in
controlling activity of the renin-angiotensin system, ACE may
play an important role in various aspects of cardiovascular
pathophysiology, including acute MI (1–5,33). Increased rates
of angiotensin II generation may lead to increases in neointi-
mal proliferation, particularly after endothelial injury, and
vascular tone, with a propensity to vasospasm. Similarly, the
vasodilatory effects of bradykinin may be disturbed by acceler-
ating its degradation. A prothrombotic state may be favored
through a number of intermediary mechanisms (33).
Although the initial report of an association between the
ACE I/D polymorphism and MI by Cambien et al. (9) has been
followed by confusion generated by discordant reports (20), an
overview of data is still consistent with an effect, although of
lesser overall magnitude than originally described (21).
That the I/D polymorphism is associated with functional
consequences was suggested by studies linking it with control
of plasma ACE levels (8,10,34,35). Rigat et al. (8) reported
that half of the interindividual variance in serum enzyme levels
could be accounted for by the polymorphism and the DD
genotype, as compared with the II genotype, was associated
with a twofold increase in plasma ACE activity. However,
MacKenzie et al. (35) later found that although there was a
clear-cut association between the I/D polymorphism and ACE
levels (in Jamaicans), another unlinked gene also appeared to
be implicated (i.e., the initial estimates of the influence of the
I/D polymorphism on serum ACE levels may have been biased
upwards). Levels of ACE in cardiac tissue also appear to be
influenced by the polymorphism (36). Nevertheless, it is rec-
ognized that the D allele in the ACE gene may simply be in
linkage disequilibrium with a nearby, pathogenetically relevant
mutation (32). Finally, pharmacologic inhibition of ACE activ-
ity may prevent myointimal proliferation after vascular injury
(37) and, through uncertain mechanisms, has been observed to
reduce the risk of recurrent MI in secondary prevention studies
(38,39).
The lack of a linear gradient in MI risk for the DD versus
ID versus II genotypes suggests a possible recessive model in
women, whereby the DD homozygote is necessary to cause a
measurable increase in disease through its effects on circulat-
ing and tissue ACE levels or other mechanisms. Women might
have a higher threshold than men for the effects of the D allele,
requiring homozygosity. However, the lack of an association
between the ID genotype and intermediate risk of MI also may
be due to chance in a study of moderate size and power.
Study limitations. This prospective study still suffers from
limitations of cross-sectional, observational studies. The diag-
nosis of MI relied on historic information rather than prospec-
tive follow-up data. Only survivors of MI were studied; theo-
retically, the DD genotype could mark enhanced survival after
MI rather than be a risk factor. A number of observations
argue against this possibility, as summarized by Singer et al.
(20) and Dakik et al. (40). In our own group, DD frequencies
were not enriched with advancing age.
A methodologic issue in earlier studies involved the mistyp-
ing of ID as DD; current methodology avoids these earlier
pitfalls (28), and any residual mistyping would need to occur
differentially in patients and control subjects. Indeed, we
undertook retyping in a subset of our groups (.10%) and
found identical results; also, our genotypic frequencies were
virtually identical to those previously reported in male or
mixed-gender groups (9,13,30,31).
The limited number of subjects in some subgroups of
interest, eg, low-risk women who are ,60 years of age,
non-smokers and non-diabetics, prevented meaningful analy-
sis. Formal logistic regression analysis was not performed to
adjust odds ratios for baseline factors. We were not able to
directly measure plasma ACE levels in our patients; others
have related ACE levels with genotype (8,36). Finally, estab-
lishment of an association does not demonstrate causality; for
example, the D allele may be in linkage disequilibrium with a
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mutation in a nearby gene that is actually responsible for
promoting MI.
Implications and conclusions. The finding in our study of
an association between the ACE DD genotype and increased
risk of MI in women (especially younger women) suggests that
genetically determined pathophysiologic mechanisms may be
in large measure independent of gender, given the observation
of an association of similar magnitude in men. However, the
determination of MI risk is multifactorial, with many environ-
mental and genetic factors interacting in a complex and as yet
incompletely understood way. Thus, it is not surprising that
associations between risk and common polymorphisms are
moderate at best (41) and have shown varying results in studies
among groups with different genetic and environmental back-
grounds.
The risk increment of the I/D polymorphism is likely to be
too small to be of routine value in individual risk assessment;
rather, studies of the polymorphism may contribute more to
pathophysiologic and epidemiologic insights in patient groups.
Continued observations in larger, well defined populations,
with prospective follow-up and control for other genetic and
environmental factors of relevance, are needed and are likely
to lead to a better understanding of the genetically determined
risk of MI, including the contribution of ACE gene activity to
MI.
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